Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 5:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 337 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Protease Inhibitor Clear all
Completed Phase 3 Interventional Results available

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

NCT00054717
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir, Ritonavir(r), Comparator Protease Inhibitor (CPI)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
96
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 10, 2026, 5:37 PM EDT
Completed Phase 3 Interventional

A Comparison of 141W94 and Indinavir in HIV-Infected Patients

NCT00002202
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Amprenavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
24
States / cities
Berkeley, California • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 10, 2026, 5:37 PM EDT
Completed Phase 1 Interventional

The Effects of HIV Protease Inhibitors in Severe Sepsis

NCT00346580
View directory record Official record
Conditions
Sepsis
Interventions
Nelfinavir
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 5, 2011 · Synced Oct 10, 2026, 5:37 PM EDT
Completed Phase 2 Interventional

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

NCT01371578
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a, ribavirin tablet
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Dothan, Alabama • Montgomery, Alabama • Beverly Hills, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 10, 2026, 5:37 PM EDT
Completed Phase 1 Interventional

A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection

NCT00001443
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
indinavir (MK-0639)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 10, 2026, 5:37 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Switching From Epzicom to Truvada

NCT00724711
View directory record Official record
Conditions
HIV Infection
Interventions
emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), abacavir (ABC)/lamivudine (3TC)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
73
States / cities
Little Rock, Arkansas • Beverly Hills, California • Fountain Valley, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 10, 2026, 5:37 PM EDT
Completed Phase 4 Interventional Results available

BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

NCT00326963
View directory record Official record
Conditions
HIV Infections
Interventions
Background ARVs, PI, enfuvirtide [Fuzeon]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
32
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Oct 10, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Atazanavir Twice Daily

NCT00357721
View directory record Official record
Conditions
HIV Infections, Protease Inhibitor
Interventions
Atazanavir Sulphate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2011 · Synced Oct 10, 2026, 5:37 PM EDT
Enrolling by invitation Phase 3 Interventional

Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency

NCT02796937
View directory record Official record
Conditions
Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
Interventions
Alpha-1 MP
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
20 Years to 72 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
6
States / cities
Phoenix, Arizona • Miami, Florida • Wilmington, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 10, 2026, 5:37 PM EDT
Completed Phase 2 Interventional

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

NCT01278134
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus placebo, RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
La Jolla, California • Sacramento, California • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 10, 2026, 5:37 PM EDT
Completed Phase 1 Interventional

Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants

NCT00002164
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
1 Day to 13 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 10, 2026, 5:37 PM EDT
Not listed Phase 4 Interventional

Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

NCT00005000
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz, Lamivudine, Keyhole-Limpet Hemocyanin, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
0 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 10, 2026, 5:37 PM EDT
Withdrawn Early Phase 1 Interventional

A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

NCT04123574
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreatic Cancer
Interventions
Talabostat Mesylate
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 10, 2026, 5:37 PM EDT
Completed Phase 4 Interventional Results available

Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

NCT00261833
View directory record Official record
Conditions
Alpha1-proteinase Inhibitor Deficiency, Emphysema
Interventions
Alpha1-proteinase inhibitor, Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
4
States / cities
Denver, Colorado • Miami, Florida • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 10, 2026, 5:37 PM EDT
Not listed Phase 1Phase 2 Interventional

APIC-CF Therapy for Mild to Moderate Osteoarthritis of the Knee

NCT02210468
View directory record Official record
Conditions
Pain, Osteoarthritis
Interventions
APIC-CF, 4 cc, APIC-CF, 2 cc, Placebo Comparator: Saline
Device · Other
Lead sponsor
Cytonics Corporation
Industry
Eligibility
21 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Townsend, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 10, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

NCT01684410
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Alpha-1 HC 100 mg, Placebo, Alpha-1 HC 200 mg
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Birmingham, Alabama • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 10, 2026, 5:37 PM EDT
Completed Phase 3 Interventional

A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy

NCT00004583
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Nelfinavir mesylate, Lamivudine, Stavudine
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
42
States / cities
Beverly Hills, California • Fountain Valley, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2009 · Synced Oct 10, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection

NCT01984294
View directory record Official record
Conditions
Chronic HCV Infection
Interventions
LDV/SOF, RBV, GS-9669
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 10, 2026, 5:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug Interactions of Echinacea, Ginseng, and Ginkgo Biloba Taken With Lopinavir/Ritonavir in Healthy Volunteers

NCT00103012
View directory record Official record
Conditions
Healthy
Interventions
Gingko Biloba, Echinacea purpurea, Panax ginseng
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 50 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Oct 10, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

NCT02525861
View directory record Official record
Conditions
Alpha1-antitrypsin Deficiency
Interventions
GLASSIA
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 10, 2026, 5:37 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor

NCT00385450
View directory record Official record
Conditions
Cardiopulmonary Bypass
Interventions
Nelfinavir/placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 10, 2026, 5:37 PM EDT
Completed Not applicable Interventional

A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3

NCT00000859
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nelfinavir mesylate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
32
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 10, 2026, 5:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Metabolism and Body Shape of Healthy Children and Children With Chronic Infections

NCT00001142
View directory record Official record
Conditions
HIV Infections, Healthy, Hyperlipidemia, Lipodystrophy
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 10, 2026, 5:37 PM EDT
Completed Not applicable Interventional

A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

NCT00002369
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Birmingham, Alabama • Fort Lauderdale, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2007 · Synced Oct 10, 2026, 5:37 PM EDT